Clinical trials: Chronic Obstructive Pulmonary Diseases
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
- Trial name
- NCT05573464
- Testing
- BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
- Where
- 91 sites in United States, Argentina and 7 more
- Volunteers
- 559 people
- Sponsor
- AstraZeneca
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- CIRRUS (NCT01233232)
- Testing
- AZD5069 50mg, AZD5069 80mg
- Where
- 8 sites in Bulgaria, Germany and 2 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults
This study aims to assess the effect of EP395 against an induced inflammation of the lung. In addition, further data about the safety and tolerability of EP395 will be collected.
- Trial name
- NCT05516316
- Testing
- EP395
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- EpiEndo Pharmaceuticals
Healthy Participants
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.
- Trial name
- NCT06368440
- Testing
- AZD6793
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Early Intervention Efficacy in COPD
This study aims to evaluate the time to escalation to triple therapy among the Japanese Chronic obstructive pulmonary disease (COPD) patients newly initiating therapy with a combination of Olodaterol and Tiotropium (herein…
- Trial name
- NCT04249310
- Testing
- Tiotropium/Olodaterol, Tiotropium
- Where
- Japan
- Volunteers
- 6,788 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1b Study of PUR1800 in Patients With COPD
This is a randomised, placebo-controlled, double-blind 3-way crossover study in which PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs.
- Trial name
- NCT04759807
- Testing
- PUR1800 250 ug, PUR1800 500 ug
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pulmatrix Inc.
Asthma, Chronic Obstructive Pulmonary Disease
ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)
The aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the FSI-10 questionnaire
- Trial name
- ANASA (NCT01475045)
- Where
- 2 sites in Greece
- Volunteers
- 1,160 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the health of patients with human Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01559051
- Testing
- Lipoaspiration with Local anesthesia
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Graft vs Host Disease
Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)
The purpose of this study is to assess the tolerability and safety of two intensity levels of Theralux extracorporeal photochemotherapy in the treatment of subjects with steroid refractory or intolerant GvHD.
- Trial name
- NCT00248365
- Testing
- Theralux extracorporeal photochemotherapy
- Where
- 4 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Kiadis Pharma
Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute…
- Trial name
- NCT00103701
- Testing
- Dasatinib
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Pulmonary Disease, Chronic Obstructive
Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00430300
- Testing
- UK-432,097
- Where
- 22 sites in Australia, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will be the first administration of CCI15106 capsules for inhalation to humans. The primary objective of the study is to investigate the safety and tolerability of single and repeat escalating doses of CCI15106 in…
- Trial name
- NCT03243760
- Testing
- CCI15106 7.5 mg capsule
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Chronic, Non Malignant Pain
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
Two stage study looking at different titration schedules in patients with moderate to severe non-malignant chronic pain. Up to 80 patients at approximately 15 centers in the US to be enrolled.
- Trial name
- NCT00485225
- Testing
- EN3270
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Durect
COPD
Assessing Exercise Capacity After PulseHaler™ Treatment in GOLD II-IV COPD Patients
Prospective, sham controlled, interventional study to evaluate the extent to which PulseHaler improves the functional status of Chronic Obstructive Lung Disease (GOLD) II-IV Chronic obstructive pulmonary disease (COPD) patients.
- Trial name
- NCT04236076
- Testing
- PulseHaler
- Volunteers
- 104 people
- Sponsor
- Respinova LTD
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
- Trial name
- NCT07116889
- Testing
- GB-0895 (SC)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Generate Biomedicines
Chronic Obstructive Pulmonary Disease, Asthma
Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of TRIMBOW using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled TRIMBOW administered via pMDI in…
- Trial name
- STORM (NCT03795350)
- Testing
- Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Respiration Rate Monitoring in COPD Patients
Assess the feasibility of using remote respiration rate monitoring as a component of home care, how respiration rate data may be used in combination with other data to potentially improve response to symptoms, and to generate…
- Trial name
- NCT03030313
- Testing
- Reassure Non-Contact Respiration Monitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ResMed
Chronic Obstructive Lung Disease
Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients
The Breathe Ventilator is a lightweight, wearable ventilator that has received U.S. FDA clearance for use in patients with respiratory difficulty.
- Trial name
- NCT01596023
- Testing
- Breathe NIOV Ventilator
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Breathe Technologies, Inc.